Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.32% |
| Mar 31, 2026 | -58.56% |
| Dec 31, 2025 | 18.56% |
| Sep 30, 2025 | -57.87% |
| Jun 30, 2025 | -18.23% |
| Mar 31, 2025 | -15.62% |
| Dec 31, 2024 | 16.29% |
| Sep 30, 2024 | 18.01% |
| Jun 30, 2024 | -148.10% |
| Mar 31, 2024 | -27.29% |
| Dec 31, 2023 | -13.69% |
| Sep 30, 2023 | -16.63% |
| Jun 30, 2023 | -29.54% |
| Mar 31, 2023 | 5.90% |
| Dec 31, 2022 | -14.25% |
| Sep 30, 2022 | -11.61% |
| Jun 30, 2022 | 16.51% |
| Mar 31, 2022 | -20.64% |
| Dec 31, 2021 | 9.35% |
| Sep 30, 2021 | -37.54% |